5 Psychedelics Grown in One Tobacco Leaf — Weizmann Study

In a single tobacco leaf, researchers at the Weizmann Institute of Science just produced five separate psychedelic compounds simultaneously. That's psilocybin (the active compound in "magic mushrooms"), DMT (dimethyltryptamine, the hallucinogen in ayahuasca), bufotenin (a tryptamine molecule found in both plants and toads), 5-MeO-DMT (5-methoxy-dimethyltryptamine, secreted from the skin glands of the Sonoran Desert toad), and a fifth tryptamine compound — all in one modified plant, at the same time. The study, published in Science Advances, was led by postdoctoral researcher Paula Berman and principal investigator Asaph Aharoni at Israel's Weizmann Institute. The reason it matters: demand for these compounds in legitimate medical research is accelerating so fast it's pushing wild species toward extinction — and threatening the Indigenous communities who have depended on them for thousands of years.

Psilocybin, DMT & Three Kingdoms: The Psychedelic Biosynthesis Science

What makes this result striking isn't just the compound count — it's how different their natural sources are. Psilocybin comes from fungi (the kingdom that includes mushrooms). DMT and bufotenin appear in Amazonian plants. 5-MeO-DMT is secreted from the skin of the Sonoran Desert toad (Incilius alvarius). These organisms span three entirely separate biological kingdoms — fungi, plants, and animals — yet the Weizmann team expressed all five compounds in a single tobacco leaf at once.

"In one leaf, we get five different psychedelics from three different kingdoms," Aharoni said. The technique centers on the tryptamine biosynthesis pathway (a sequence of chemical reactions in living cells that manufactures tryptamine-class molecules — the molecular family shared by psilocybin, DMT, bufotenin, and related psychoactive compounds). By inserting genes encoding this pathway into tobacco leaf cells, the team rewired the plant's chemistry without changing its outward appearance or growth rate.

Why Tobacco? Plant Biosynthesis Design Choices That Matter

Tobacco is a workhorse of plant genetics research, not a natural psychedelic host. Its leaf cells are well-characterized, fast-growing, and highly amenable to genetic modification — making it a blank-canvas organism (a plant whose internal chemistry can be reprogrammed to produce compounds entirely foreign to its normal biology, similar to how industrial breweries engineer yeast to produce insulin or specialty enzymes).

The team built several deliberate constraints into the research:

• Non-inheritable modification — The inserted genes are engineered to not transfer to offspring. This is a structural fail-safe (a technical constraint preventing modified DNA from spreading into wild plant populations — a concern that has plagued other genetically modified crop programs).
• No wild organisms harmed in production — Unlike extracting from mushrooms, cacti, or live toads, this approach requires no wild harvesting at all.
• Proof-of-concept scope — The research demonstrates feasibility. Pharmaceutical-scale production has not yet begun.
• Reduced chemical hazards — Compared to synthetic production (making these molecules through traditional laboratory chemistry), plant-based biosynthesis avoids hazardous precursor reactants and cuts multi-step waste generation significantly.

Aharoni described the team's philosophy: "One of our motivations was to really understand better what these species do, so that we can mimic what they do."

The Extinction Crisis Behind Psychedelic Biosynthesis Research

The Sonoran Desert toad is disappearing. Wild populations are declining 25–40% annually in some regions, driven by illegal poaching — people capturing or milking the toads specifically for 5-MeO-DMT, which has surged in demand from psychedelic-assisted therapy programs (clinical treatments using controlled doses of psychedelic compounds under medical supervision to treat PTSD, depression, and anxiety disorders). The Weizmann team cites this directly as a motivation.

The pressure is broader than one species:

• Peyote cacti — Over-harvested across Mexican and Indigenous North American territories; takes 10–15 years to reach maturity in the wild
• Ayahuasca vines — Rising commercial retreat-industry demand in South America threatens forest ecosystems and long-established Indigenous sourcing rights
• Sacred mushroom species — Foraging pressure is increasing as psychedelic decriminalization expands in U.S. cities and states

The communities hardest hit are often those with the deepest historical relationship to these plants. "Over-harvesting endangers the natural availability of these species for native peoples and Indigenous groups," said Berman. "We have so much respect for the knowledge that they provide us, and we just want to add to this knowledge."

From Sacred Ritual to Phase 3 Psychedelic Medicine Trials

The clinical pipeline for psychedelic medicine has expanded dramatically. Here's where each of the five compounds stands today:

• Psilocybin — Received FDA Breakthrough Therapy designation (a fast-track status given to treatments that show substantial improvement over existing options) for treatment-resistant depression; multiple Phase 3 trials are underway globally
• DMT — Active clinical programs for major depressive disorder and addiction; trials ongoing at institutions including Imperial College London
• 5-MeO-DMT — Early Phase 2 trials for PTSD showing favorable outcomes; typically given in single-session, clinician-supervised formats
• Bufotenin — Less clinically advanced, but present in traditional ceremonial preparations now under formal ethnobotanical and pharmacological study

The supply problem is structural. As trials scale from dozens to thousands of participants, demand for pharmaceutical-grade material multiplies. Synthetic production is possible but generates hazardous chemical waste and requires multi-step processing. Wild harvesting is both ecologically damaging and legally complicated. The Weizmann approach — if scaled — offers a third path.

Ethical Guardrails in Psychedelic Plant Engineering

Two choices distinguish this research from standard pharmaceutical plant engineering. First: the non-heritable design. These plants are engineered so their modifications literally cannot reproduce into the next generation — zero risk of psychedelic tobacco spreading uncontrolled into agricultural or wild environments. Second: the team's explicit acknowledgment of Indigenous communities as the source of foundational knowledge. Pharmaceutical research has a long history of commercially exploiting traditional plant knowledge without adequately crediting or compensating its origins; the Weizmann team framed their work as a response to that history, not a continuation of it.

Key open questions remain. No clinical timeline has been announced for using this plant-derived material in trials. Regulatory status varies sharply: in the United States, psilocybin remains a Schedule I controlled substance (the most restrictive federal category — reserved for substances with no currently accepted medical use and high abuse potential, a classification many researchers argue is scientifically obsolete). Israel, where Weizmann operates, uses a different licensing framework for research use. And the question of how any resulting pharmaceutical products will benefit the Indigenous communities whose knowledge underpins this research is, as yet, unanswered.

If you're tracking the intersection of biotechnology and psychedelic medicine — for clinical, investment, or policy purposes — this paper in Science Advances is worth reading in full. The Weizmann approach represents a careful, ecologically-motivated answer to a real and worsening supply crisis. Watch for follow-on Weizmann publications in 2026 on yield scaling and compound purity. And if you want to understand how AI tools are accelerating drug discovery and biomedical research workflows, explore our guides on AI for research automation.

Related Content — Get Started | Guides | More News